ES2128363T3 - Anticuerpo especifico para cdw52 para el tratamiento de la esclerosis multiple. - Google Patents

Anticuerpo especifico para cdw52 para el tratamiento de la esclerosis multiple.

Info

Publication number
ES2128363T3
ES2128363T3 ES92924783T ES92924783T ES2128363T3 ES 2128363 T3 ES2128363 T3 ES 2128363T3 ES 92924783 T ES92924783 T ES 92924783T ES 92924783 T ES92924783 T ES 92924783T ES 2128363 T3 ES2128363 T3 ES 2128363T3
Authority
ES
Spain
Prior art keywords
treatment
multiple sclerosis
cdw52
specific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924783T
Other languages
English (en)
Inventor
H Prof Waldmann
Geoffrey Dr Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2128363T3 publication Critical patent/ES2128363T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN ANTICUERPO QUE RECONOCE EL ANTIGENO CDW52 EN EL TRATAMIENTO DE LA ESCLEROSIS MULTIPLE. PREFERIBLEMENTE EL ANTICUERPO ES EL ANTICUERPO HUMANIZADO DEL ANTICUERPO HUMANIZADO CAMPATH-1H.
ES92924783T 1991-12-04 1992-12-04 Anticuerpo especifico para cdw52 para el tratamiento de la esclerosis multiple. Expired - Lifetime ES2128363T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919125768A GB9125768D0 (en) 1991-12-04 1991-12-04 Therapeutic method

Publications (1)

Publication Number Publication Date
ES2128363T3 true ES2128363T3 (es) 1999-05-16

Family

ID=10705671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924783T Expired - Lifetime ES2128363T3 (es) 1991-12-04 1992-12-04 Anticuerpo especifico para cdw52 para el tratamiento de la esclerosis multiple.

Country Status (17)

Country Link
US (2) US6120766A (es)
EP (1) EP0616537B1 (es)
JP (1) JP3383303B2 (es)
KR (1) KR100271333B1 (es)
AT (1) ATE177011T1 (es)
AU (1) AU3089692A (es)
CA (1) CA2124964C (es)
DE (1) DE69228556T2 (es)
DK (1) DK0616537T3 (es)
ES (1) ES2128363T3 (es)
GB (1) GB9125768D0 (es)
GR (1) GR3029683T3 (es)
IL (1) IL103981A (es)
MX (1) MX9207032A (es)
MY (1) MY111961A (es)
WO (1) WO1993010817A1 (es)
ZA (1) ZA929446B (es)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
EP2034009B1 (en) 2002-02-08 2014-01-15 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
EP1539929B1 (en) 2002-06-28 2013-04-10 Life Technologies Corporation Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2066352B1 (en) * 2006-09-13 2015-12-02 Alcafleu Management GmbH & Co. KG Treatment of multiple sclerosis (ms) with campath-1h
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
ES2612558T3 (es) 2007-02-16 2017-05-17 Genzyme Corporation Método de identificación de riesgo para el trastorno del tiroides
EP3456733A1 (en) * 2007-05-11 2019-03-20 Genzyme Corporation Methods of producing a secreted protein
MY160126A (en) * 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
CA2842368A1 (en) 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
CA2848410A1 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
AU2013222284A1 (en) 2012-02-22 2014-08-07 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
AU2013222288A1 (en) 2012-02-22 2014-08-14 The Trustees Of The University Of Pennsylvania Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
CN112375846A (zh) 2012-07-13 2021-02-19 宾夕法尼亚大学董事会 评估用于施用的转导t细胞的适用性的方法
HRP20250822T1 (hr) 2012-07-13 2025-09-26 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a
SG11201408787PA (en) 2012-07-13 2015-01-29 Univ Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
JP6493692B2 (ja) * 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
AU2015339743C1 (en) 2014-10-31 2021-04-22 The Trustees Of The University Of Pennsylvania Altering gene expression in modified T cells and uses thereof
HK1243333A1 (zh) 2014-10-31 2018-07-13 The Trustees Of The University Of Pennsylvania 用於修饰的t细胞的方法和组合物
WO2016069993A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016133779A1 (en) 2015-02-16 2016-08-25 The Trustees Of The University Of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
AU2016228080B2 (en) 2015-03-02 2020-11-12 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune tolerance induced by PD-L1
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017040195A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
WO2017059796A1 (en) 2015-10-08 2017-04-13 Shanghai Sidansai Biotechnology Co., Ltd Activation and expansion of t cells
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US20190153064A1 (en) 2016-04-15 2019-05-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric alloantigen receptor t cells
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR20190057275A (ko) 2016-07-18 2019-05-28 헬릭스 바이오파마 코포레이션 암을 치료하기 위한 암배아 항원 관련 세포 부착 분자 6에 대한 car 면역 세포
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
AU2017382902A1 (en) 2016-12-21 2019-07-18 TCR2 Therapeutics Inc. Engineered T cells for the treatment of cancer
EP4032550A3 (en) 2017-01-05 2022-10-19 Innovative Cellular Therapeutics Holdings, Ltd. Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
EP3638295A1 (en) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US12365733B2 (en) 2017-12-29 2025-07-22 Cellectis Method for improving production of car T cells
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765054A4 (en) 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3813885A4 (en) 2018-05-02 2022-01-12 The Trustees of The University of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
WO2019236593A1 (en) 2018-06-05 2019-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7227374B2 (ja) 2018-08-13 2023-02-21 ルートパス・ジェノミクス，インコーポレーテッド 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用
TW202026006A (zh) 2018-08-30 2020-07-16 美商Ｔｃｒ２療法股份有限公司 使用融合蛋白進行tcr再程式化之組成物及方法
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN113631575A (zh) 2019-03-15 2021-11-09 笛卡尔疗法股份有限公司 抗bcma嵌合抗原受体
SG11202110956RA (en) 2019-04-05 2021-10-28 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
WO2021248061A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US20250205335A1 (en) 2022-03-17 2025-06-26 Hangzhou Chengyuan Biotechnology Co., Ltd. Synthetic tumor-infiltrating lymphocytes (tils)
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
JPH07504888A (ja) 1995-06-01
US20050118172A1 (en) 2005-06-02
CA2124964A1 (en) 1993-06-10
EP0616537A1 (en) 1994-09-28
MY111961A (en) 2001-03-31
MX9207032A (es) 1993-07-01
KR100271333B1 (ko) 2000-11-01
GR3029683T3 (en) 1999-06-30
IL103981A0 (en) 1993-05-13
DE69228556D1 (de) 1999-04-08
ZA929446B (en) 1993-08-19
DK0616537T3 (da) 1999-09-27
AU3089692A (en) 1993-06-28
GB9125768D0 (en) 1992-02-05
DE69228556T2 (de) 1999-07-08
JP3383303B2 (ja) 2003-03-04
EP0616537B1 (en) 1999-03-03
WO1993010817A1 (en) 1993-06-10
IL103981A (en) 1997-07-13
CA2124964C (en) 2005-03-15
US6120766A (en) 2000-09-19
ATE177011T1 (de) 1999-03-15
HK1011618A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
ES2128363T3 (es) Anticuerpo especifico para cdw52 para el tratamiento de la esclerosis multiple.
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ES2159560T3 (es) Inhibicion del crecimiento del pelo.
DE69229278D1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
NZ568769A (en) Human monoclonal antibodies against CD20
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
NO960684D0 (no) Monoklonalt antistoff som induserer apoptose
ES2113891T3 (es) Anticuerpos monoclonales de raton.
ES2058490T3 (es) Metodo de reducir respuestas de inmunoglobulina e.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
ES2062032T3 (es) Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
ES2062762T3 (es) Metodo para tratar el choque septico.
DE69216600D1 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
ZA202202380B (en) Anti-human p40 protein domain antibody and use thereof
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.
ES2055066T3 (es) Anticuerpos monoclonales que reconocen el extremo n del gamma polipeptido natriuretico atrial, hibridomas que los producen y su preparacion y aplicacion.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2107545T3 (es) Anticuerpos policlonales dirigidos contra la hirudina y su utilizacion para la identificacion, la purificacion inmunologica y la determinacion cuantitativa de la hirudina.
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
AR133022A1 (es) Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco
MX9302629A (es) Purificacion del inhibidor-activador de plasminogeno 2 por cromatografia de inmunoafinidad.
AR122241A1 (es) Composiciones anti-cd112r y métodos
ES2076526T3 (es) Antagonistas de bcrf1 para tratar infecciones del virus epstein-barr.
ES2051870T3 (es) Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 616537

Country of ref document: ES